Display options
Cite
Rogers J, Baker M. Understanding the most commonly billed diagnoses in primary care: Hyperlipidemia. Nurse Pract. 2020;45(8):42-48doi: 10.1097/01.NPR.0000681792.32984.96.
Rogers, J., & Baker, M. (2020). Understanding the most commonly billed diagnoses in primary care: Hyperlipidemia. The Nurse practitioner, 45(8), 42-48. https://doi.org/10.1097/01.NPR.0000681792.32984.96
Rogers, Julia, and Baker, Manisa. "Understanding the most commonly billed diagnoses in primary care: Hyperlipidemia." The Nurse practitioner vol. 45,8 (2020): 42-48. doi: https://doi.org/10.1097/01.NPR.0000681792.32984.96
Rogers J, Baker M. Understanding the most commonly billed diagnoses in primary care: Hyperlipidemia. Nurse Pract. 2020 Aug;45(8):42-48. doi: 10.1097/01.NPR.0000681792.32984.96. PMID: 32701880.
Copy Download .nbib Format: NLM
Share it on

Nurse Pract. 2020 Aug;45(8):42-48. doi: 10.1097/01.NPR.0000681792.32984.96.

Understanding the most commonly billed diagnoses in primary care: Hyperlipidemia.

The Nurse practitioner

Julia Rogers, Manisa Baker

PMID: 32701880 DOI: 10.1097/01.NPR.0000681792.32984.96

Abstract

This installment in the series on the most commonly billed diagnoses in primary care focuses on hyperlipidemia. This article discusses the pathophysiologic processes of hyperlipidemia as well as how the clinical manifestations and treatments are linked to the pathogenesis of disease.

References

  1. ICD-10 Resources: Clinical Concepts Series. Centers for Medicare and Medicaid Services. 2015. www.cms.gov/Medicare/Coding/ICD10/Downloads/ICD10ListservClinicalConcepts.pdf. - PubMed
  2. Rui P, Hing E, Okeyode T. National ambulatory medical care survey: 2014 state and national summary tables. 2014. www.cdc.gov/nchs/data/ahcd/namcs_summary/2014_namcs_web_tables.pdf. - PubMed
  3. Hollenberg S, Heitner S. Cardiology in Family Practice: A Practical Guide. New York, NY: Springer; 2012. - PubMed
  4. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–2024. - PubMed
  5. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016;316(19):1997–2007. - PubMed
  6. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528. - PubMed
  7. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8th ed. St. Louis, MO: Elsevier; 2019. - PubMed
  8. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–e1143. - PubMed
  9. American Heart Association. Cholesterol management guide for healthcare practitioners. 2018. www.heart.org/-/media/files/health-topics/cholesterol/chlstrmngmntgd_181110.pdf. - PubMed
  10. Hong KN, Fuster V, Rosenson RS, Rosendorff C, Bhatt DL. How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD. J Am Coll Cardiol. 2017;70(17):2171–2185. - PubMed
  11. Saely CH, Saely RR, Drexel H. Treatment of hyperlipidemia: consensus and controversies. Cardiol Plus. 2017;2:18–25. - PubMed
  12. Adnan T, Ahmad M, Chaudhri WM, et al. Pathophysiology of dyslipidemia and its management by PCSK9 inhibitors: a literature review. Intern Med Med Invest J. 2018;3(3):92–99. - PubMed
  13. Chinook Health Region. Building healthy lifestyles: vascular protection dyslipidemia clinical guide. 2006. www.cna-aiic.ca/-/media/nurseone/page-content/pdf-fr/dyslipidema_clinical_guide.pdf?la=fr&hash=1072A4E291767A9688C55C679781531E16B7DB6E. - PubMed
  14. Nguyen TN, Hu D, Chen SL, Kim M-H, Grines CL, Latif F. Management of Complex Cardiovascular Problems. Chichester, West Sussex: John Wiley & Sons; 2016. - PubMed
  15. Chang H-C, Sung C-W, Lin M-H. Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):596–605. - PubMed
  16. Scheel P, Meyer J, Blumenthal RS, Martin SS. Lipoprotein(a) in clinical practice. 2019. www.acc.org/latest-in-cardiology/articles/2019/07/02/08/05/lipoproteina-in-clinical-practice. - PubMed
  17. American College of Cardiology. ASCVD risk estimator plus. 2020. http://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate. - PubMed
  18. Vijan S. Screening for lipid disorders in adults. UpToDate. 2019. wwwuptodate.com. - PubMed
  19. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163. - PubMed
  20. Ridker PM, Danielson E, Fonseca FAH. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207. - PubMed
  21. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–2410. - PubMed
  22. Toth PP, Worthy G, Gandra SR, et al. Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia. J Am Heart Assoc. 2017;6(10):1–13. - PubMed
  23. Kaur N, Pandey A, Negi H, et al. Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One. 2014;9(4):e94585. - PubMed
  24. Centers for Disease Control and Prevention. ICD-10-CM official guidelines for coding and reporting. 2019. www.cdc.gov/nchs/icd/data/10cmguidelines-FY2019-final.pdf. - PubMed
  25. Palmer C. New directions in managing dyslipidemia. J Nurse Pract. 2019;15(1):73–79. - PubMed

Publication Types